# SUPERNUS PHARMACEUTICALS, INC.

SUPERNUS PHARMACEUTICALS, INC. is a public company listed on Nasdaq as SUPN, headquartered in Rockville, MD, United States.

## Company overview

- **Legal name:** SUPERNUS PHARMACEUTICALS, INC.
- **Former names in filing history:** SUPERNUS PHARMACEUTICALS INC (2006-03-06 to 2019-06-12)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Rockville, MD, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: SUPN
- **SEC CIK:** 0001356576

## About

SUPERNUS PHARMACEUTICALS, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001356576, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-03-02, it reported annual revenue of USD 718,952,000; net income of USD -38,550,000; total assets of USD 1,452,648,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $719.0M (USD 718,952,000)
- **Net income:** -$38.5M (USD -38,550,000)
- **Total assets:** $1.5B (USD 1,452,648,000)
- **Cash and equivalents:** $128.4M (USD 128,448,000)
- **Operating cash flow:** $47.3M (USD 47,331,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $661.8M (USD 661,817,000)
- **Net income:** $73.9M (USD 73,865,000)
- **Total assets:** $1.4B (USD 1,368,073,000)
- **Cash and equivalents:** $69.3M (USD 69,331,000)
- **Operating cash flow:** $172.0M (USD 171,951,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $667.2M (USD 667,238,000)
- **Net income:** $60.7M (USD 60,711,000)
- **Total assets:** $1.7B (USD 1,702,508,000)
- **Cash and equivalents:** $93.1M (USD 93,120,000)
- **Operating cash flow:** $116.8M (USD 116,826,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $579.8M (USD 579,775,000)
- **Net income:** $53.4M (USD 53,424,000)
- **Total assets:** $1.7B (USD 1,689,152,000)
- **Cash and equivalents:** $203.4M (USD 203,434,000)
- **Operating cash flow:** $127.1M (USD 127,127,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2026-08-03 — period 2026-08-03 — FORM 8-K
- Form 8-K — filed 2026-08-03 — period 2026-08-03 — FORM 8-K
- Form 10-Q — filed 2026-08-03 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-08-03 — period 2026-08-03 — 8-K
- Form 8-K — filed 2026-08-03 — period 2026-08-01 — FORM 8-K
- Form 8-K — filed 2026-07-22 — period 2026-07-22 — 8-K
- Form 8-K — filed 2026-06-18 — period 2026-06-18 — 8-K
- Form 8-K — filed 2026-05-20 — period 2026-05-17 — 8-K
- Form 10-Q — filed 2026-05-05 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-05 — period 2026-05-05 — 8-K
- Form DEF 14A — filed 2026-04-30 — period 2026-06-18 — FORM DEF 14A
- Form 8-K — filed 2026-04-22 — period 2026-04-22 — 8-K

---

Updated: 2026-10-23T05:02:54.863002+00:00

Canonical page: https://altss.com/profile/supernus-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology